AORTMEDIUM SIGNALFINANCIAL10-K

AORT achieved profitability turnaround with net income swinging from -$13.4M loss to $9.8M profit while significantly reducing debt and expanding share count through what appears to be acquisition activity.

The dramatic financial improvement combined with substantial debt reduction ($314M to $215M) and strengthened equity position suggests successful operational turnaround and improved capital structure management. However, the 14% increase in outstanding shares and major capital expenditure surge indicate potential dilutive acquisition activity that investors should monitor for integration success and return on invested capital.

Comparing 2026-02-18 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

AORT demonstrated strong financial recovery with profitability returning (+$23M swing in net income), operating cash flow increasing 79% to $40M, and debt declining 32% while stockholders' equity grew 62%. The company significantly ramped up capital expenditures (249% increase to $39M) and expanded share count 14%, suggesting major growth investments or acquisitions. Despite higher interest expense and SG&A costs, the overall financial picture shows a company emerging from losses with improved cash generation, stronger balance sheet, and strategic investments in growth, though investors should monitor the returns on the substantial capital deployment.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
+266.9%
$1.5M$5.6M

Share repurchases increased 266.9% — management returning capital, signals confidence in intrinsic value.

Capital Expenditure
Cash Flow
+249%
$11.2M$39.0M

Capital expenditure jumped 249% — major investment cycle underway; assess returns on deployment.

Net Income
P&L
+173.1%
-$13.4M$9.8M

Net income grew 173.1% — bottom-line growth signals improving overall business health.

Operating Cash Flow
Cash Flow
+79.3%
$22.2M$39.9M

Operating cash flow surged 79.3% — exceptional cash generation, highest quality earnings signal.

Stockholders Equity
Balance Sheet
+62.3%
$276.2M$448.2M

Equity base grew 62.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Liabilities
Balance Sheet
+52%
$66.8M$101.6M

Current liabilities surged 52% — significant near-term obligations; verify ability to meet short-term debt.

Interest Expense
P&L
+38.8%
$18.2M$25.3M

Interest expense surged 38.8% — significant debt increase or rising rates materially impacting earnings.

Total Debt
Balance Sheet
-31.6%
$314.3M$215.1M

Debt reduced 31.6% — deleveraging strengthens balance sheet and reduces financial risk.

SG&A Expense
P&L
+24.8%
$181.5M$226.5M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Current Assets
Balance Sheet
+23.4%
$290.1M$358.1M

Current assets grew 23.4% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-02-18
PRIOR — 2025-02-28
ADDED
As of February 13, 2026 the number of outstanding shares of Common Stock of the registrant was 47,883,897 .
Abdominal stent grafts include our E-xtra Design Engineering, E-nside TM , Artivex TM , E-tegra TM , E-ventus TM BX, Tuva TM BX, and E-liac TM products.
Surgical sealants include BioGlue Surgical Adhesive ( BioGlue ) products.
Recent real-world data presented at the 2024 AATS showed five-year outcomes for 229 On-X aortic heart valve patients managed at a low INR of 1.5-2.0 (after 3 months standard therapy) reduces risk of major bleeding by 87% with no increase in thromboembolic events and no valve thrombosis when compared to standard INR of 2.0-3.0.
Thoracic Stents and Stent Grafts E-vita Open NEO The E-vita Open NEO is the next generation of the E-vita Open Plus hybrid stent graft, with an updated delivery system and improved handling.
+7 more — sign up free →
REMOVED
As of February 21, 2025 the number of outstanding shares of Common Stock of the registrant was 42,047,888 .
Abdominal stent grafts include our E-xtra Design Engineering (including Artivex TM ), E-nside TM , E-tegra TM , E-ventus TM BX, Tuva BX, and E-liac TM products.
Surgical sealants include our BioGlue Surgical Adhesive products ( BioGlue ).
On January 1, 2022 we converted our state of incorporation from Florida to Delaware, and on January 18, 2022 we changed our name from CryoLife, Inc.
Our common stock is listed on the New York Stock Exchange under the symbol of AORT and traded under the symbol CRY prior to January 24, 2022.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →